**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a cohort study of 22 patients conducted between 14 March 2020 and 15 April 2020, 18 patients (8 men and 10 women) in their 40s−70s were described, who developed COVID-19 infection during immunosuppressive treatment with azathioprine, ciclosporin, everolimus, mycophenolate, mycophenolate mofetil, tacrolimus or unspecified steroids following kidney transplant. Two out of these 18 patients died due to COVID-19 infection \[*routes and time to reactions onset not stated; not all dosages stated*\].

The patients, who had undergone kidney transplant, had been receiving immunosuppressive treatment with tacrolimus, mycophenolate and unspecified steroids (n=6), everolimus, mycophenolate and unspecified steroids (n=3), tacrolimus and unspecified steroids (n=2), ciclosporin and unspecified steroids (n=1), ciclosporin, mycophenolate and unspecified steroids (n=1), ciclosporin, mycophenolate, azathioprine and unspecified steroids (n=1), tacrolimus, azathioprine and unspecified steroids (n=1), ciclosporin, azathioprine and unspecified steroids (n=2) and tacrolimus, mycophenolate, unspecified steroids and mycophenolate mofetil (n=1). In patients receiving mycophenolate, the daily dose was 1g. After 1−402 months of the kidney transplant, the patients were admitted (two patients in ICU) due to COVID-19 infection with symptoms including fever, cough, dyspnoea, digestive symptoms, neurological symptoms or asthenia. The diagnosis was confirmed based on positive COVID-19 real-time PCR assay and CT scan findings. In two patients, hospital course was complicated by worsening confusion, neurologic status deterioration associated with severe hypercapnia, hypoxaemia, pneumonia or severe respiratory distress. Three of the 18 patients also developed other infections including pulmonary bacterial infection, acute pyelonephritis associated with bacteraemia and BK virus viraemia, respectively.

The immunosuppressive treatment in the patients was managed by discontinuation of mycophenolate, mycophenolate mofetil and azathioprine in all the patients with decrease in the dose of tacrolimus, everolimus and ciclosporin (n=13) and discontinuation of everolimus (n=1). For COVID-19, 13 patients were treated with hydroxychloroquine 400mg twice daily on day 1 (off-label), and two patients with hydroxychloroquine 400mg twice daily on day 1 and methylprednisolone (off-label). Eleven patients needed oxygen supplementation via nasal cannula, while two of them also needed invasive ventilation. Thirteen patients were discharged after 2−26 days of hospitalisation and two patients died due to COVID-19 infection, while three patients remained hospitalised. The patient with pulmonary bacterial infection was treated with cefuroxime, while the patient with acute polyonephritis associated with bacteraemia was treated with unspecified antibiotics (with rapid response) \[*not all outcomes stated*\].
